Hiro Capital Doubles Down on Digital Sports With its Latest Investment in PlayerData - Builds on Games & DSports Portfolio Acceleration
8.4.2021 08:00:00 EEST | Business Wire | Press release
Hiro Capital – the London / Luxembourg VC fund investing across Games, Esports, Streaming and Digital Sports – has further strengthened its portfolio by leading a $2.3m investment in PlayerData.
Edinburgh, UK-based PlayerData’s mission is to transform the way grass-roots and professional sports teams train, using software, analytics, gamification and wearable technology.
- In its first year live, PlayerData has already captured more than 10,000 team sessions and >50 million meters of athlete play in UK grass-roots Soccer and Rugby, and these KPIs are strongly accelerating.
- The $2.3m raise will be used to supercharge PlayerData’s growth across multiple sports and to expand internationally.
PlayerData combines frictionless ease-of-use with sports-science Machine Learning.
- PlayerData drives powerful team network effects, with each club using PlayerData bringing 5 more clubs onto the platform.
- PlayerData’s AI algorithms predict player injuries before they happen and its tools allow coaches to replay key moments from the game, modelling different outcomes based on player positioning.
This announcement marks Hiro Capital’s 12th investment in 2020/21 and its 4th in Gamified Fitness and Sports tech. PlayerData joins fellow Digital Sports startups FitXR (London), Zwift (California/London) and NURVV (London) in the Hiro Capital portfolio, alongside eight Games studios and Games technology firms across the US, Europe and the UK.
The rise of Digital Sports and Connected Fitness
Digital Sports and Connected Fitness are star growth sectors of 2020/21. Global Connected Fitness revenues grew 30% in 2020 and Health and Fitness app downloads grew +47% YoY to c.700m, accelerated by a global focus on health and wellbeing during lockdowns.
Unicorn scale stars of the sector include Peloton, Tonal, Mirror and Hiro’s portfolio investment, Zwift, as well as major strategic Sports and Wellness segments within Apple (Watch 6 and Fitness+), Google (Fitbit), Nike (Nike App), and others. In Digital Sports, alongside Zwift, Hiro’s lead investments powered ahead:
FitXR: The leading VR Fitness App & Service
- FitXR has made extraordinary progress since Hiro invested, with revenues up 10x over the last 2 quarters and now >$1m per month;
- Described by Oculus VP Content Mike Verdu as having “incredible traction” and “one of the highest retention rates on the [Oculus VR] platform”*, and name-checked by Mark Zuckerberg** on his recent “The Information” podcast on VR/AR and the Metaverse.
*”From Bear to Bull: How Oculus Quest 2 is Changing the Game for VR”, Mike Verdu, VP Content, Oculus 2nd Feb 2020
**Mark Zuckerberg on Mind Reading, Apple, and the Race to Mainstream VR, March 8th 2021
NURVV: Patented Smart Running insole and Biomechanical Data Leader
- Since launch in mid-2020, NURVV Run has generated data on >100 million foot-strikes from >125,000km run by athletes around the world, building what is already the world’s largest database of detailed running foot technique;
- Olympic gold-medallist and world-record holder Dame Kelly Holmes has joined NURVV as global brand ambassador; USA Olympian Jared Ward, UK elite coach Harry Jameson, the Financial Times, WIRED, Runner’s World and CNET have all recommended NURVV;
- With iOS, Android, Garmin ConnectIQ, Strava and Apple Watch integrations live, the company is leading running innovation with unique features such as Pace Coach, Footstrike Workout and Running Health score.
- "Knowledge really is power and in this respect NURVV Run is a game changer" said Dame Kelly Holmes.
PlayerData: AI Driven Team Performance
Roy Hotrabhvanon, cofounder & CEO of PlayerData, is a former international archer who narrowly missed out on selection for the Rio Olympics in 2016 for the Thailand national team. Hayden Ball, cofounder and CTO is a CompSci expert in firmware and cloud infrastructure who designed, built, and launched a distributed SaaS solution for the Edinburgh Fringe.
On the Hiro investment, Roy said - “Our mission is to bring fine grained data and insight to clubs across team sports, helping them supercharge their game-making, improve player performance, and avoid injury. We leverage our platform and big data to generate biometric insights applicable at any level - from grassroots to the Premier League. Due to the team network effect, the PlayerData community is fast-growing across the U.K. and overseas. Our ultimate goal is to implement cutting-edge insights from pioneering wearables that are applicable to any team in any discipline at any level. Hiro Capital as an investment partner, shares this commitment to our mission. It’s great to have Cherry, Luke and Ian’s belief, counsel and expertise to help us further our vision.”
Cherry Freeman, co-founding Partner at Hiro says: “PlayerData ticks all of our key boxes: a huge TAM with over 3m grass-roots clubs; a deep moat built on shared player data, machine learning and highly actionable predictive algorithms; compelling customer network effects; and a really impressive yet humble founding team. We are delighted to be leading this investment round in this exciting DSports innovator”
Luke Alvarez, Managing Partner at Hiro says: “In a year when lockdown accelerated digital adoption and kept us all out of the gym, companies like Nurvv, FitXR, Zwift and Peloton helped people stay fit, healthy, and biomechanically self-aware. 2020 super-charged connected fitness and PlayerData is our latest exciting investment in this accelerating macro trend.”
About Hiro Capital
Hiro Capital is a London / Luxembourg technology Venture Capital fund which invests in UK, US and European innovators in Games, Metaverse Technology, Esports and Digital Fitness. Hiro Capital generally invests at the post-seed Series A and B stages. We invest both in front-end Content creators in Games, Esports and Digital Sports and in deep tech Metaverse applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies.
We back experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.
We are Games, Esports and Sports investors who are also Games, Esports and Sports entrepreneurs. We are entrepreneurs who back entrepreneurs. Our core belief is that Games, Esports and Digital Sports will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future.
The fund was founded by Luke Alvarez (Managing Partner) the former co-founding CEO & President of Nasdaq-listed, Inspired Entertainment; Ian Livingstone, OBE, CBE (Partner), the former chairman of Tomb Raider publisher Eidos plc, co-founder of Games Workshop and author of the Fighting Fantasy gamebook series; and Cherry Freeman (Partner), the co-founder of global community and e-commerce brand LoveCrafts. https://hiro.capital/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005773/en/
Contact information
Aimee Soulsby
aimee@burlington.cc
+447951080547
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
